"","Num","POD","SD","%","Genes","KE"
"FOLLICULAR HYPERKERATOSIS","1","5.34e-06",NA,"25","436656","INCREASE ADENOMAS/CARCINOMAS FOLLICULAR CELL"
"SANDAL GAP","1","7.02e-06",NA,"20","767754","N/A GAP"
"GO:0042311","2","1.30153755228192e-05","0.161196288799782","13.33","561701, 30442","IMPAIRED VASODILATION"
"BLADDER CANCER","2","1.76332073089384e-05","0.336214638606161","4.76","386966, 565173","INCREASE CANCER"
"GO:0046879","2","2.1028456909626e-05","0.236349344174274","16.67","569038, 792391","DECREASED GNRH PULSATILITY/RELEASE IN HYPOTHALAMUS; DECREASED LH SURGE FROM ANTERIOR PITUITARY; INCREASED SECRETION OF GNRH FROM HYPOTHALAMUS; DECREASED GNRH PULSATILITY/RELEASE IN HYPOTHALAMUS; DECREASED LH SURGE FROM ANTERIOR PITUITARY"
"SYNAPTIC TRANSMISSION GLUTAMATERGIC","2","2.18494851197917e-05","0.00210822012047158","15.38","335625, 561701","REDUCED PRESYNAPTIC RELEASE OF GLUTAMATE"
"GO:0001963","1","2.2e-05",NA,"8.33","561701","INCREASE DOPAMINERGIC ACTIVITY; DECREASED DOPAMINERGIC ACTIVITY"
"GO:0051899","1","2.2e-05",NA,"4.76","561701","OCCURRENCE A PAROXYSMAL DEPOLARIZING SHIFT; PROLONGED DEPOLARIZATION OF NEURONAL MEMBRANE"
"GO:0060080","1","2.2e-05",NA,"20","561701","INCREASED INHIBITORY POSTSYNAPTIC POTENTIAL"
"GO:0060291","1","2.2e-05",NA,"7.14","561701","DECREASED LONG-TERM POTENTIATION LTP"
"ADRENAL HYPERPLASIA","1","2.5e-05",NA,"25","399692","INCREASE HYPERPLASIA TERMINAL BRONCHIOLAR CELLS; INCREASE HYPERPLASIA FOLLICULAR CELLS; INCREASE HYPERPLASIA UROTHELIAL; HYPERPLASIA OVARIAN STROMAL CELLS; INCREASED LACTOTROPH HYPERPLASIA AND HYPERTROPHY"
"GO:0030331","1","3.29e-05",NA,"11.11","30265","INCREASED ER BINDING TO DNA CLASSICAL PATHWAY; INCREASED ER BINDING TO TF TO DNA NON-CLASSICAL PATHWAY"
"NCRNAS INVOLVED IN WNT SIGNALING IN HEPATOCELLULAR CARCINOMA","1","3.29e-05",NA,"2.08","30265","INCREASE HERITABLE MUTATIONS IN OFFSPRING"
"HEPATOCELLULAR CARCINOMA","1","3.29e-05",NA,"7.69","30265","FORMATION HEPATOCELLULAR AND BILE DUCT TUMORS; INCREASE ADENOMAS/CARCINOMAS HEPATOCELLULAR; TUMORIGENESIS HEPATOCELLULAR CARCINOMA"
"GO:0007588","3","3.39990772529272e-05","0.252468166633837","21.43","561701, 30442, 791518","INCREASE BILIARY EXCRETION TH GLUCURONIDE"
"GO:0010468","4","3.86429897360124e-05","0.0920928089509594","25","559504, 30482, 30681, 30567","DECREASED TRANSCRIPTION OF GENES BY AR"
"GLUTATHIONE METABOLIC PROCESS","1","3.97e-05",NA,"10","553575","GLUTATHIONE SYNTHESIS; GLUTATHIONE HOMEOSTASIS"
"NEURODEGENERATION","1","3.99e-05",NA,"6.67","378453","N/A NEURODEGENERATION"
"DRUG INDUCTION OF BILE ACID PATHWAY","1","4.08e-05",NA,"8.33","324340","DECREASED BILE FLOW"
"FARNESOID X RECEPTOR PATHWAY","1","4.08e-05",NA,"10","324340","ACTIVATION NR1H4"
"CTOME ACTIVATION OF AMPK DOWNSTREAM OF NMDARS","3","4.25391712674328e-05","0.116871798311438","23.08","337223, 445164, 554127","INHIBITION NMDARS; OVERACTIVATION NMDARS"
"GO:1904019","2","4.43025958607394e-05","0.508451361277666","9.09","791518, 494133","DECREASE APOPTOSIS OF CILIATED EPITHELIAL CELLS"
"SQUAMOUS CELL CARCINOMA","2","4.48089276818805e-05","0.653241715769822","20","100004133, 436656","INCREASE PAPILLOMAS/CARCINOMAS SQUAMOUS CELLS; INCREASE RESPIRATORY OR SQUAMOUS METAPLASIA; SQUAMOUS METAPLASIA ABERRANT BASAL CELLS"
"VASCULAR CALCIFICATION","1","4.76e-05",NA,"20","30482","OSTEOPOROSIS AND VASCULAR CALCIFICATION BONE DETERIORATION"
"GO:0019932","7","4.78951453381822e-05","0.0979059211196008","11.48","335625, 561701, 368488, 30442, 30664, 573689, 321442","INCREASED SECOND MESSENGER PRODUCTION"
"GO:0004364","1","4.79e-05",NA,"20","406736","DOWN REGULATION GSS AND GSTS GENE"
"GO:0003158","4","4.95871491629659e-05","0.111829210162573","16.67","30265, 323696, 30317, 100329779","IMPAIRMENT ENDOTHELIAL NETWORK"
"ARYL HYDROCARBON RECEPTOR PATHWAY","1","5.34e-05",NA,"2.08","100150054","UP REGULATION CYP1A1; ACTIVATION AHR"
"CYTOPLASMIC RIBOSOMAL PROTEINS","8","5.58051792355306e-05","0.0445567588534378","5.56","560828, 445053, 557397, 405888, 436759, 336710, 337007, 407690","OCCURRENCE CYTOPLASMIC VACUOLIZATION PODOCYTE"
"GO:0070330","3","5.58129233565688e-05","0.0488722138130052","37.5","100150054, 368352, 324340","REDUCTION IN OVARIAN GRANULOSA CELLS AROMATASE CYP19A1; INHIBITION AROMATASE; DECREASED AROMATASE CYP19A1 MRNA"
"G OOCYTE MEIOSIS","1","5.68e-05",NA,"2.5","406685","REDUCED MEIOTIC PROPHASE I/METAPHASE I TRANSITION OOCYTE"
"LIVER X RECEPTOR PATHWAY","2","5.70599684542499e-05","0.103005209401318","16.67","368352, 324340","ACTIVATION LXR; ACTIVATION LXR ALPHA"
"ABNORMAL NEURON MORPHOLOGY","2","5.73389919688165e-05","0.111353166307451","12.5","378453, 445164","HYPERPOLARISATION NEURON"
"GO:0070265","1","5.74e-05",NA,"9.09","140540","INCREASE TISSUE DEGENERATION NECROSIS & ATROPHY; INCREASED ONCOTIC NECROSIS"
"NEUROINFLAMMATION","1","5.74e-05",NA,"8.33","140540","N/A NEUROINFLAMMATION"
"PROGRESSIVE HEARING IMPAIRMENT","1","5.74e-05",NA,"12.5","140540","REDUCED HEARING; REDUCED HEARING"
"VENTRICULAR ARRHYTHMIA","1","5.74e-05",NA,"14.29","140540","OCCURRENCE CARDIAC ARRHYTHMIA"
"CTOME REGULATED NECROSIS","2","6.25975239126916e-05","0.0575512773005732","9.52","566604, 406766","INCREASE NECROSIS TERMINAL BRONCHIOLAR CELLS"
"GO:0007051","3","6.6872706999144e-05","0.363368611984394","11.11","767754, 335495, 321283","DISORGANIZATION SPINDLE"
"GO:0016209","3","6.94298503751004e-05","0.117404362777754","27.27","553575, 406736, 246226","OXIDATION GLUTATHIONE"
"GO:0005184","2","7.09535059035141e-05","0.363816427172297","66.67","335625, 321442","SP SUBSTANCE P RELEASE LOCAL INCREASE OF SP"
"REGULATION OF POTASSIUM ION TRANSPORT","2","7.09535059035141e-05","0.363816427172297","12.5","335625, 321442","INHIBITION ETHER-A-GO-GO ERG VOLTAGE-GATED POTASSIUM CHANNEL"
"GO:0006412","11","7.43103473016057e-05","0.0533145117618911","10.19","405839, 541548, 327515, 322256, 560828, 445053, 557397, 405888, 436759, 337007, 407690","ALTERED PROTEIN PRODUCTION"
"GO:0004882","4","7.45004585140211e-05","0.350337910967827","11.43","405897, 30265, 321875, 30767","N/A ANDROGEN RECEPTOR ANTAGONISM; AGONISM ANDROGEN RECEPTOR; DECREASED ANDROGEN RECEPTOR ACTIVITY; ACTIVATION ANDROGEN RECEPTOR"
"GO:0036475","2","7.52249958457958e-05","0.253968908257459","40","30265, 58122","N/A NEURONAL DYSFUNCTION"
"ELEVATED RED CELL ADENOSINE DEAMINASE LEVEL","1","7.80999999999999e-05",NA,"5.56","445053","INCREASED CYCLIC ADENOSINE MONOPHOSPHATE"
"PURE RED CELL APLASIA","1","7.80999999999999e-05",NA,"5","445053","N/A METHEMOGLOBINEMIA DECREASED HEMOGLOBIN HEMATOCRIT RED BLOOD CELL NUMBER"
"GO:1903008","2","7.88701464433787e-05","0.480428643221212","15.38","30664, 394111","DISRUPTION LYSOSOME"
"GO:0042701","2","7.98749021908634e-05","0.592521789090717","5.88","378972, 30681","DECREASED PROGESTERONE FROM CORPUS LUTEUM"
"SMOOTH MUSCLE CELL PROLIFERATION","2","8.7365897236851e-05","0.299916543551409","7.69","30265, 791518","HYPERTROPHY/HYPERPLASIA SMOOTH MUSCLE"
"ABNORMAL CARDIAC TEST","5","9.46654784437658e-05","0.13832704418198","38.46","399692, 30483, 58076, 321442, 57936","INCREASED CARDIAC ARRTHYMIA"
"OXIDATIVE STRESS","2","9.59708289012865e-05","0.271068492951391","8.33","553575, 791518","PROPAGATION OXIDATIVE STRESS; N/A OXIDATIVE STRESS; INCREASE OXIDATIVE STRESS / ACTIVATION PMK-1 P38 MAPK; INCREASED OXIDATIVE STRESS; INCREASE OXIDATIVE STRESS / ACTIVATION PMK-1 P38 MAPK; INCREASE ENERGETIC DEMANDS AND THEREFORE METABOLIC STRESS; INCREASED ENERGETIC DEMANDS AND THEREFORE METABOLIC STRESS"
"GO:0006936","9","9.78692881867104e-05","0.0753405892945204","16.36","30725, 30442, 796865, 30483, 30429, 321442, 100329779, 57936, 58071","REDUCTION ABDOMINAL MUSCLE CONTRACTION; OVERACTIVATION MUSCLE CONTRACTION"
"GO:0001508","1","9.82999999999999e-05",NA,"6.67","30725","ALTERED ACTION POTENTIAL"
"GO:0005216","1","9.82999999999999e-05",NA,"4.17","30725","IMPAIRED ION CHANNELS"
"GO:0007268","1","9.82999999999999e-05",NA,"2.86","30725","REDUCTION NEURONAL SYNAPTIC INHIBITION"
"GO:0015464","1","9.82999999999999e-05",NA,"12.5","30725","ACTIVATION NICOTINIC ACETYLCHOLINE RECEPTOR"
"GO:0019226","1","9.82999999999999e-05",NA,"8.33","30725","REDUCTION ECDYSIS MOTONEURON BURSTS"
"INHIBITION ACETYLCHOLINESTERASE ACHE","1","9.82999999999999e-05",NA,"9.09","30725","INHIBITION ACETYLCHOLINESTERASE ACHE"
"GO:0048469","7","0.000100176595002813","0.112054136162525","29.17","399483, 30265, 30442, 30705, 30541, 559921, 322309","INCREASED OOCYTE MATURATION"
"GO:0006633","4","0.000103199579314693","0.18084541136659","13.79","324340, 327075, 246226, 797132","SYNTHESIS DE NOVO FA; INCREASED DE NOVO FA SYNTHESIS; INCREASED DE NOVO FA SYNTHESIS"
"GO:0008213","1","0.000106",NA,"14.29","100000709","ALKYLATION PROTEIN"
"CYANOSIS","4","0.000106542019311256","0.17183079440499","21.05","30725, 30483, 58076, 57936","N/A CYANOSIS OCCURS"
"INCREASED PULMONARY VASCULAR RESISTANCE","3","0.000109440161630691","0.280437075417927","75","30483, 58076, 57936","INCREASE VASCULAR RESISTANCE"
"GO:0016055","3","0.000111009495170209","0.164954313257406","13.04","322106, 30265, 30556","ALTERATION WNT PATHWAY"
"GO:0042446","3","0.000114196030831568","0.321438468101444","10.71","399692, 324340, 334098","INCREASE LUTEINIZING HORMONE LH; REPRESSED EXPRESSION OF STEROIDOGENIC ENZYMES"
"PROSTAGLANDIN SYNTHESIS AND REGULATION","3","0.000125540951593962","0.381999219935379","11.54","30442, 334098, 246226","REDUCTION PROSTAGLANDIN E2 CONCENTRATION; REDUCED PROSTAGLANDIN F2ALPHA CONCENTRATION PLASMA"
"NEOPLASM OF THE SKIN","6","0.000130046590446156","0.138454929297847","18.18","30265, 100004133, 30705, 436656, 562149, 30225","SENSITISATION SKIN"
"INCREASED SUSCEPTIBILITY TO FRACTURES","8","0.000130177845045234","0.105017917140563","22.86","30725, 406626, 30265, 30705, 266799, 378453, 406691, 30767","INCREASED DISEASE SUSCEPTIBILITY"
"GO:0006636","3","0.000140610315121717","0.274193624919423","25","327075, 246226, 797132","UP REGULATION UNSATURATED FATTY ACID"
"ABNORMAL BLOOD POTASSIUM CONCENTRATION","3","0.00014405408847734","0.302794613262117","25","399692, 266799, 334098","INCREASED BLOOD POTASSIUM CONCENTRATION"
"PARALYSIS","3","0.000149409841128486","0.170825089187417","13.04","30705, 378453, 562149","INDUCTION SOMATIC MUSCLE PARALYSIS; INDUCTION PHARYNGEAL MUSCLE PARALYSIS"
"GO:0045333","9","0.000150121099814487","0.0420405891262744","12.5","393577, 415253, 335774, 140540, 573689, 562149, 436850, 317746, 393793","INCREASE OXIDATIVE METABOLISM"
"ABNORMALITY OF ADRENAL PHYSIOLOGY","7","0.000156663096754497","0.0951587139558663","7.61","30265, 399692, 30483, 334098, 406713, 337598, 30225","INCREASE RENAL PATHOLOGY DUE TO VTG DEPOSITION; DECREASED RENAL ABILITY TO DILUTE URINE; OCCURRENCE KIDNEY TOXICITY; INCREASED KIDNEY FAILURE"
"GO:0006120","1","0.000162",NA,"3.7","573689","BINDING OF INHIBITOR NADH-UBIQUINONE OXIDOREDUCTASE COMPLEX I"
"GO:0008137","1","0.000162",NA,"11.11","573689","INHIBITION NADH-UBIQUINONE OXIDOREDUCTASE COMPLEX I"
"ABNORMAL SOCIAL BEHAVIOR","1","0.000162",NA,"3.85","573689","ABNORMAL FORAGING ACTIVITY AND BEHAVIOR"
"GO:0099536","11","0.000162463757060199","0.0958435678226617","9.91","335625, 561701, 30725, 30265, 550403, 30664, 100003922, 557397, 798575, 30767, 554127","DECREASED NEURONAL NETWORK FUNCTION IN ADULT BRAIN; DECREASED NEURONAL NETWORK FUNCTION IN ADULT BRAIN"
"BREAST CANCER PATHWAY","5","0.000169220744924428","0.112867889126737","4.39","378972, 30265, 100004133, 386966, 30705","N/A BREAST CANCER"
"GO:0001516","1","0.000176",NA,"25","246226","REDUCED PROSTAGLANDIN F2ALPHA SYNTHESIS OVARY; DECREASED PROSTAGLANDIN F2ALPHA SYNTHESIS OVARY"
"GO:0004666","1","0.000176",NA,"25","246226","INHIBITION CYCLOOXYGENASE ACTIVITY; INHIBITION CYCLOOXYGENASE 1 ACTIVITY"
"GO:0015631","3","0.000176409523295381","0.410838991730206","15.79","567253, 767754, 436819","BINDING TUBULIN"
"DECREASED FERTILITY","6","0.000177418784952581","0.120896558653275","7.89","399692, 30705, 30126, 30483, 562350, 436749","IMPAIRED FERTILITY; DECREASED SPERM QUANTITY OR QUALITY IN THE ADULT DECREASED FERTILITY; REDUCTION CUMULATIVE FECUNDITY AND SPAWNING; DECREASED SPERM QUANTITY OR QUALITY IN THE ADULT DECREASED FERTILITY; DECREASED SPERM QUANTITY OR QUALITY IN THE ADULT DECREASED FERTILITY; DECREASED TESTOSTERONE"
"ANTERIOR PITUITARY AGENESIS","2","0.000178490335872842","0.473444295598104","40","30126, 58076","INCREASED SECRETION OF LH FROM ANTERIOR PITUITARY"
"ABNORMAL PROLACTIN LEVEL","2","0.000182929494614729","0.480988437479524","25","30126, 30225","DECREASED PROLACTIN"
"DECREASED BODY WEIGHT","35","0.000186614504531099","0.0300311917909533","15.49","327601, 368488, 399483, 767754, 559504, 399692, 100004133, 327075, 30442, 30705, 544667, 678540, 30483, 58076, 266799, 394190, 334098, 436656, 406713, 286747, 140540, 573689, 406462, 324256, 405861, 368229, 555364, 445053, 562149, 393963, 406691, 30767, 436850, 368206, 100000709","DECREASED BODY WEIGHT"
"ABNORMAL CIRCULATING RENIN","2","0.000191049731745428","0.624521251284107","33.33","399692, 334098","REDUCTION GONADOTROPINS CIRCULATING CONCENTRATIONS"
"GO:0010463","4","0.000202243958482249","0.152996914145161","33.33","30265, 30705, 30225, 368206","INCREASED PROLIFERATION OF MESENCHYMAL CELLS"
"GO:0009611","13","0.000202841003673962","0.111294776800262","11.61","561701, 566604, 386966, 323696, 30126, 30483, 30482, 58076, 791518, 559921, 100003922, 494133, 369194","ACCUMULATION DAMAGED MITOCHONDRIAL DNA"
"GO:0007269","4","0.000203767174497313","0.364531035735689","16","561701, 550403, 100003922, 798575","OVERACTIVATION NEURONOTRANSMITTER RELEASE"
"ABNORMALITY OF REPRODUCTIVE SYSTEM PHYSIOLOGY","19","0.000205204482900922","0.0431679807210439","18.45","378972, 399483, 30265, 399692, 100004133, 405839, 541548, 30705, 30126, 30483, 792391, 140540, 562350, 368229, 436749, 323855, 30225, 30767, 557518","N/A IMPAIRMENT OF REPRODUCTIVE CAPACITY"
"GLUCOCORTICOID RECEPTOR PATHWAY","1","0.000207",NA,"4.17","399483","ACTIVATION GLUCOCORTICOID RECEPTOR"
"ABNORMAL NASAL MORPHOLOGY","22","0.000210691288196391","0.0531341644896372","14.19","399483, 767754, 30265, 30442, 30705, 30483, 30482, 58076, 406264, 114426, 406462, 324256, 368229, 406685, 323855, 555364, 445053, 30225, 30767, 368206, 140618, 100000709","INCREASE SITE OF CONTACT NASAL TUMORS"
"ABNORMALITY OF THE ENDOMETRIUM","1","0.000216",NA,"9.09","562149","INCREASED HYPERPLASIA GLANDULAR EPITHELIAL CELLS OF ENDOMETRIUM; INCREASE HYPERPLASIA GLANDULAR EPITHELIAL CELLS OF ENDOMETRIUM; INCREASED ADENOSQUAMOUS CARCINOMAS OF ENDOMETRIUM"
"HYPERTENSION ASSOCIATED WITH PHEOCHROMOCYTOMA","1","0.000216",NA,"14.29","562149","INCREASE HYPERTENSION"
"PSYCHOGENIC NON EPILEPTIC SEIZURE","1","0.000216",NA,"7.69","562149","OCCURRENCE EPILEPTIC SEIZURE"
"INCREASED CIRCULATING PROLACTIN CONCENTRATION","3","0.000229057941263616","0.249143036368163","60","30265, 368229, 30225","INCREASED PROLACTIN SECRETION; INCREASED PROLACTIN EXPOSURE"
"GO:0004620","1","0.000232",NA,"20","791518","INHIBITION PHOSPHOLIPASE A"
"LUNG FIBROSIS","1","0.000232",NA,"2.78","791518","LUNG FIBROSIS"
"BRADYCARDIA","1","0.000232",NA,"16.67","321442","INCREASED ATRIOVENTRICULAR BLOCK AND BRADYCARDIA"
"JNK CASCADE","1","0.000232",NA,"4.55","321442","ACTIVATION JNK"
"CTOME METABOLISM OF PORPHYRINS","1","0.000232",NA,"33.33","791518","ACCUMULATION HIGHLY CARBOXYLATED PORPHYRINS"
"GO:0042060","12","0.00023477029031433","0.124344484052766","13.64","561701, 566604, 386966, 323696, 30126, 30483, 30482, 58076, 791518, 100003922, 494133, 369194","FAILURE IN VASCULAR REPAIR MECHANISMS UNRESOLVED BLOOD LOSS HEMORRHAGE"
"ABNORMALITY OF THE BLADDER","8","0.000235782806107841","0.0858792829659361","15.38","399483, 378453, 406264, 555364, 562149, 30225, 550537, 368206","REDUCED POSTERIOR SWIM BLADDER INFLATION; REDUCED ANTERIOR SWIM BLADDER INFLATION; INCREASE URINARY BLADDER CALCULI"
"GO:0007249","6","0.00023666781076503","0.0801497123028184","13.95","30265, 791518, 100329779, 797132, 114445, 436819","INHIBITION NUCLEAR FACTOR KAPPA B NF-KB"
"GO:0043542","4","0.000250935109149253","0.125535389234598","11.43","100150054, 30705, 791518, 797132","INCREASED MIGRATION ENDOTHELIAL CELLS"
"HEART DEVELOPMENT","19","0.000251778778321494","0.0611248863551193","15.08","116713, 566604, 30265, 386966, 30126, 30483, 30482, 58076, 100034503, 30664, 321442, 555364, 100329779, 30225, 368206, 57936, 369194, 58071, 100000709","ALTERED LARVAL DEVELOPMENT; IMPAIRED DEVELOPMENT"
"GO:0044414","6","0.000255613321439277","0.322142061206839","15","436799, 286779, 321453, 337223, 445164, 554127","SUPPRESSION IMMUNE SYSTEM"
"GO:0006954","13","0.000267874607878157","0.106056379845081","11.11","335625, 561701, 100000085, 30442, 323696, 791518, 406713, 327321, 321442, 246226, 565173, 30225, 30767","INCREASE INFLAMMATION; INCREASE INFLAMMATION CORNEAL CELLS; INFILTRATION INFLAMMATORY CELLS; INCREASED INFLAMMATION; CHRONIC COUGH RESPIRATORY IRRITABILITY"
"TUBE FEEDING","5","0.000277699595891591","0.287041673774239","29.41","327075, 30705, 793321, 406264, 406685","INHIBITION FEEDING"
"ABNORMALITY OF THE OVARY","13","0.000279659805239218","0.0565238452768021","22.81","378972, 30265, 399692, 405839, 541548, 30705, 544667, 30483, 562350, 368229, 436749, 562149, 550537","REDUCED PROSTAGLANDINS OVARY"
"GO:0003714","3","0.000283787697579656","0.342838108810914","15","567253, 797132, 406691","STABILIZATION PPAR ALPHA CO-REPRESSOR"
"ABNORMAL CIRCULATING ESTROGEN LEVEL","5","0.000284017745973884","0.153085237753095","35.71","399692, 30483, 562350, 436749, 30225","INCREASED CIRCULATING ESTROGEN LEVELS"
"GLOMERULAR SCLEROSIS","3","0.000286160146343319","0.255371383075303","21.43","140540, 562350, 562149","DECREASED GLOMERULAR FILTRATION"
"ELECTRON TRANSPORT CHAIN","10","0.000297875422897009","0.146051905535385","14.71","445283, 415253, 335774, 405812, 327075, 553575, 140540, 573689, 562149, 393793","DISRUPTION MITOCHONDRIAL ELECTRON TRANSPORT CHAIN"
"GO:1903409","3","0.000298989918490221","0.422900961925119","12","100150054, 140540, 30767","INCREASE ROS PRODUCTION; PRODUCTION REACTIVE OXYGEN SPECIES"
"GO:0009790","28","0.000309911940748794","0.051732877235247","16.57","116713, 415187, 566604, 399483, 30265, 30705, 544667, 30541, 30126, 30483, 58076, 100034503, 792391, 30317, 30379, 394111, 393993, 555364, 562840, 100329779, 436759, 30225, 368206, 57936, 140618, 369194, 394172, 554127","DEFECT OF EMBRYOGENESIS"
"GO:0048870","25","0.000324019601432638","0.0469949457596813","12.5","378972, 415187, 569038, 406853, 30265, 100150054, 30442, 386966, 323696, 30705, 544667, 30664, 791518, 393545, 100003922, 321555, 100329779, 797132, 30225, 30767, 393274, 368206, 57936, 369194, 554127","INCREASED MOTILITY"
"ABNORMAL OVARIAN MORPHOLOGY","10","0.000324557611103116","0.0694610621113318","27.03","378972, 399692, 30705, 544667, 30483, 562350, 368229, 436749, 562149, 550537","PROMOTION OVARIAN GRANULAR CELL TUMORS; DECREASED OVARIAN E2; PROMOTION OVARIAN ADENOMAS"
"GO:0040011","31","0.000326612652168165","0.0391756888856918","13.66","561701, 378972, 415187, 569038, 406853, 30265, 100150054, 30442, 386966, 323696, 30705, 544667, 142985, 30664, 791518, 393722, 393545, 100003922, 321555, 393993, 100329779, 565173, 797132, 30225, 30767, 393274, 368206, 57936, 369194, 554127, 436819","INCREASED LOCOMOTION; INCREASED MUSCULAR WAVES IN FOOT; DECREASED LOCOMOTION"
"ABNORMALITY OF THE PITUITARY GLAND","12","0.00034187881509474","0.074423771043305","25","399483, 30265, 399692, 30705, 30126, 30483, 58076, 562350, 368229, 436749, 30225, 393963","INCREASED ADENOMAS PITUITARY"
"GO:0006281","11","0.000353174945922377","0.133022913101694","12.94","405897, 393162, 100004133, 394048, 337598, 286747, 335495, 553705, 321875, 797132, 100000709","N/A INSUFFICIENT OR INCORRECT DNA REPAIR; INCREASED INSUFFICIENT REPAIR OR MIS-REPAIR OF PRO-MUTAGENIC DNA ADDUCTS; OVERWHELMED MITOCHONDRIAL DNA REPAIR MECHANISMS; INCREASED DNA DAMAGE-REPAIR"
"GO:0001525","2","0.000353216647399298","0.55322097744717","5.41","544667, 794176","REDUCTION ANGIOGENESIS; INCREASED ANGIOGENESIS"
"GO:0005102","26","0.000367786726150991","0.0580422037015457","12.5","335625, 561701, 58098, 368488, 566604, 405897, 30265, 30442, 327515, 386966, 323696, 30705, 30664, 794176, 436656, 321442, 100003922, 323855, 393993, 555364, 797132, 30225, 30767, 393274, 436821, 369194","DECREASED TESTOSTERONE BINDING TO ANDROGEN RECEPTOR HYPOTHALAMUS"
"ABNORMAL CORNEAL EPITHELIUM MORPHOLOGY","1","0.000376",NA,"7.69","100004133","INCREASED ACCUMULATION OF ALPHA2U MICROGLOBULIN PROXIMAL TUBULAR EPITHELIUM"
"ABNORMALITY OF THE MITOCHONDRION","6","0.000376854346755016","0.186854650609805","4.76","335774, 266799, 394190, 140540, 573689, 436850","INJURY MITOCHONDRIA; DAMAGING MITOCHONDRIA; N/A MITOCHONDRIAL DYSFUNCTION 1"
"ADRENERGIC RECEPTOR SIGNALING PATHWAY","1","0.000377",NA,"12.5","30664","INCREASED ACTIVITY BETA-2 ADRENERGIC RECEPTOR; ACTIVATION BETA-2 ADRENERGIC RECEPTOR"
"GO:0016310","19","0.000381032249531382","0.0699070772643964","15.2","378972, 405897, 399483, 393162, 64274, 322106, 386966, 30705, 544667, 30664, 30307, 30681, 327321, 436608, 394028, 100329779, 565173, 550537, 393274","ACTIVATION SP1"
"GO:0006629","26","0.000383714391616309","0.0448789342124106","12.62","378972, 116713, 445327, 327601, 558088, 399692, 100150054, 368352, 324340, 327075, 30705, 544667, 58076, 394190, 334098, 405860, 406713, 393722, 406736, 405861, 246226, 562840, 797132, 322309, 30670, 436819","ALTERATION LIPID METABOLISM"
"ABNORMAL BLOOD SODIUM CONCENTRATION","1","0.000387",NA,"11.11","30705","DECREASED SODIUM CONDUCTANCE 2; DECREASED SODIUM REABSORPTION"
"HYPOTHALAMIC GONADOTROPIN RELEASING HORMONE DEFICIENCY","1","0.000387",NA,"25","30705","REDUCED GONADOTROPIN RELEASING HORMONE HYPOTHALAMUS"
"ENDOMETRIAL CANCER","6","0.000398360941439208","0.173549378675922","8.82","378972, 492763, 30265, 100004133, 386966, 30705","INCREASE ENDOMETRIAL ADENOCARCINOMAS"
"GO:0005488","148","0.000399434453407208","0.00889862898148723","13.75","335625, 378972, 58098, 394243, 567253, 406301, 30632, 415187, 259303, 405897, 767754, 393162, 30725, 445283, 393577, 559504, 432372, 406853, 406626, 64274, 322106, 386806, 30265, 405812, 399692, 100150054, 368352, 324340, 619259, 100004133, 386709, 553324, 405839, 541548, 327515, 322256, 386966, 323696, 30705, 544667, 793321, 30541, 30126, 567969, 550403, 30483, 30482, 58076, 142985, 406615, 100034503, 30664, 553575, 394048, 791518, 792391, 378453, 555643, 406264, 559921, 30317, 30379, 30065, 794176, 798920, 405860, 30307, 393669, 30681, 327321, 436608, 334195, 58122, 337598, 286747, 30575, 30080, 30429, 568332, 192325, 321442, 797715, 393545, 406462, 324256, 323462, 30567, 394111, 402974, 553705, 436749, 568298, 100004610, 563298, 394028, 321555, 140620, 246226, 407634, 393993, 555364, 321875, 406310, 100329779, 560828, 445053, 557397, 336710, 565173, 30486, 562149, 797132, 322309, 30225, 324121, 445404, 447922, 393963, 406691, 494133, 402972, 30767, 550537, 436850, 317746, 436821, 368206, 57936, 30556, 140618, 369194, 445035, 436628, 30670, 557518, 58071, 323361, 394172, 445164, 554127, 402989, 114445, 30100, 322815, 393793, 436819, 100000709, 100004929","INCREASED BINDING OF CHEMICALS TO 2U SERUM"
"GO:0001775","24","0.000400069119178715","0.0514023385806173","12.24","561701, 566604, 100000085, 406549, 30265, 327075, 386966, 323696, 791518, 794176, 321442, 393545, 100003922, 323462, 335495, 445413, 100329779, 557397, 30225, 30767, 550537, 373077, 436819, 100000709","ACTIVATION DENDRITIC CELLS"
"ABNORMALITY OF BLOOD AND BLOOD FORMING TISSUES","28","0.000408755274198994","0.042596704453167","6.93","445327, 327601, 30265, 368352, 544667, 58076, 553575, 394190, 791518, 436656, 406713, 337598, 140540, 573689, 405861, 368229, 394028, 445053, 562149, 30225, 393963, 406691, 30767, 550537, 368206, 369194, 30670, 58071","DAMAGING RED BLOOD CELLS; HEMOLYSIS"
"HYPERACTIVITY","11","0.000413183718407628","0.123924804528291","22","368488, 399483, 30705, 793321, 796865, 30483, 114426, 406685, 368206, 557518, 554127","INDUCTION ATAXIA PARALYSIS OR HYPERACTIVITY; INCREASED ATAXIA PARALYSIS OR HYPERACTIVITY; N/A ATAXIA PARALYSIS OR HYPERACTIVITY"
"PERICARDIAL EFFUSION","1","0.000417",NA,"25","368229","INCREASE PERICARDIAL EDEMA"
"ABNORMAL RESPIRATORY SYSTEM MORPHOLOGY","27","0.000426989340486691","0.0441123011227233","18.37","30725, 559504, 406626, 30442, 30705, 30483, 58076, 266799, 378453, 406713, 337598, 562350, 406462, 324256, 368229, 436749, 555364, 30225, 393963, 406691, 30767, 550537, 368206, 57936, 369194, 58071, 100000709","INCREASED RESPIRATORY DISTRESS/ARREST"
"GO:0030154","7","0.000438811498966117","0.109482923367782","10.77","30541, 30126, 393545, 563298, 555364, 30486, 30670","DIFFERENTIATION OF MYOFIBROBLAST"
"GO:0001816","16","0.000442252064121601","0.0914929822292167","13.33","335625, 30265, 100150054, 323696, 30705, 30483, 58076, 791518, 406713, 327321, 553705, 436749, 565173, 797132, 30767, 369194","NON-NEURONAL PRODUCTION OF TNF EPITHELIAL IRRITATION; PRODUCTION OF NERVE GROWTH FACTOR  EPITHELIAL IRRITATION; NON-NEURONAL PRODUCTION OF IL-8/CXCL1 EPITHELIAL IRRITATION"
"PEPTIDYL LYSINE MODIFICATION","10","0.000450415298935141","0.130086165801736","14.08","393162, 30265, 335236, 562350, 568298, 565173, 797132, 322309, 114445, 100000709","N/A COVALENT BINDING TO PROTEIN POSSIBLY LYSINE RESIDUE"
"CTOME SIGNALING BY TYPE 1 INSULIN LIKE GROWTH FACTOR 1 RECEPTOR IGF1R","2","0.000461356694976891","0.053970534768164","15.38","378972, 30705","INCREASED IGF-1 MOUSE"
"GO:0050673","17","0.000471440014778276","0.0837847037545928","20.73","116713, 399483, 30265, 30442, 386966, 30705, 544667, 791518, 792391, 797132, 30225, 494133, 30767, 550537, 393274, 368206, 369194","INCREASE REGENERATIVE CELL PROLIFERATION TUBULAR EPITHELIAL CELLS; INCREASE REGENERATIVE CELL PROLIFERATION TERMINAL BRONCHIOLAR EPITHELIAL CELLS"
"GO:0019098","1","0.000477",NA,"11.11","30670","ALTERED REPRODUCTIVE BEHAVIOUR; REDUCED BROOD CARE"
"ABNORMAL THYROID HORMONE LEVEL","1","0.000477",NA,"5","30670","INCREASED HEPATIC THYROID HORMONE UPTAKE/TRANSPORT; DECREASE SERUM THYROID HORMONE T4/T3; DECREASED THYROXINE T4 IN SERUM; DECREASED THYROXINE T4 IN TISSUES; DECREASED TRIIODOTHYRONINE T3 IN TISSUES; INCREASED TRIIODOTHYRONINE T3 IN TISSUES"
"MATING BEHAVIOR","1","0.000477",NA,"11.11","30670","REDUCED ABILITY TO ATTRACT SPAWNING MATES"
"REPRODUCTIVE BEHAVIOR","1","0.000477",NA,"10","30670","REDUCED SPAWNING BEHAVIOR"
"ABNORMAL LUNG MORPHOLOGY","25","0.000493741992489368","0.0485958527225586","19.53","30725, 559504, 406626, 30442, 30705, 30483, 58076, 266799, 406713, 337598, 562350, 324256, 368229, 436749, 555364, 30225, 393963, 406691, 30767, 550537, 368206, 57936, 369194, 58071, 100000709","INCREASE ADENOMAS/CARCINOMAS BRONCHIOLOALVEOLAR"
"IMMUNOLOGIC HYPERSENSITIVITY","7","0.000519037138668053","0.218840491626194","30.43","399483, 30705, 100034503, 114426, 406691, 30767, 368206","INCREASE ALLERGIC RESPIRATORY HYPERSENSITIVITY RESPONSE"
"ABNORMAL CIRCULATING CHOLESTEROL CONCENTRATION","3","0.000525378013469564","0.171077093280865","27.27","406713, 562350, 368229","DECREASED CHOLESTEROL; PERTURBATION OF CHOLESTEROL"
"POSITIVE REGULATION OF GENE EXPRESSION","21","0.000535433628403198","0.0700845196207914","11.6","335625, 116713, 393162, 30265, 100150054, 386966, 30483, 30482, 58076, 30664, 791518, 436656, 327321, 553705, 436749, 100329779, 30225, 30767, 140618, 394172, 100000709","ALTERED GENE EXPRESSION"
"LIPID METABOLISM PATHWAY","1","0.00055",NA,"8.33","378972","DAMAGE LIPID BILAYER"
"CTOME ACTIVATION OF BAD AND TRANSLOCATION TO MITOCHONDRIA","1","0.00055",NA,"9.09","378972","DIRECT MITOCHONDRIAL INHIBITION; MITOCHONDRIAL IMPAIRMENT"
"TISSUE ISCHEMIA","5","0.000561129572164335","0.396796964542155","33.33","30265, 30483, 58076, 57936, 369194","OCCURRENCE RENAL ISCHEMIA"
"ABNORMAL HYPOTHALAMUS PHYSIOLOGY","2","0.00058224737010999","0.125438318012527","22.22","30705, 30225","REDUCED PROSTAGLANDIN E2 CONCENTRATION HYPOTHALAMUS; DECREASE E2 BLOOD CONCENTRATIONS AT HYPOTHALAMUS"
"ABNORMALITY OF THE ABDOMINAL ORGANS","31","0.000591202915091149","0.0420206608475346","18.34","378972, 327601, 399483, 558088, 30265, 386709, 282672, 544667, 678540, 58076, 394190, 791518, 792391, 378453, 406713, 337598, 140540, 573689, 405861, 368229, 394028, 555364, 562149, 393963, 406691, 30767, 550537, 368206, 557518, 58071, 100000709","IMPAIRED DEVELOPMENT OF REPRODUCTIVE ORGANS"
"GO:0019904","19","0.000601876432873783","0.0680112301609561","15.45","492763, 393162, 30265, 323696, 30705, 30541, 30126, 378453, 555643, 393669, 58122, 797132, 402972, 550537, 30670, 394172, 402989, 114445, 436819","N/A INTERFERENCES WITH SH-/SELEN-PROTEINS"
"CHOLESTASIS","5","0.000607918410914849","0.290659493104466","14.29","327601, 678540, 394190, 792391, 406713","INCREASED CHOLESTASIS; CHOLESTASIS PATHOLOGY"
"GO:0072358","19","0.000609534030410864","0.0698374941074023","17.12","116713, 30265, 100150054, 386966, 30705, 544667, 567969, 30483, 58076, 791518, 559921, 100329779, 797132, 30225, 30767, 550537, 368206, 57936, 369194","ALTERED CARDIOVASCULAR DEVELOPMENT/FUNCTION"
"GO:0004872","20","0.000627015190745142","0.0778093385879483","8.37","335625, 561701, 30632, 569038, 30725, 64274, 30442, 386966, 30705, 544667, 793321, 321442, 100003922, 563298, 555364, 30486, 30225, 564017, 369194, 30670","ACTIVATION PXR/SXR"
"REGULATION OF CELL DEATH","38","0.000630371854700427","0.0389325340796117","14.18","335625, 561701, 378972, 116713, 386808, 567253, 368488, 566604, 492763, 406766, 445283, 406853, 30265, 100150054, 494065, 30442, 30705, 793321, 30541, 567969, 30483, 58076, 30664, 791518, 406264, 58122, 140540, 323462, 402974, 555364, 797132, 322309, 30225, 494133, 368206, 140618, 369194, 30670","N/A CELL INJURY/DEATH"
"REGULATION OF PROTEOLYSIS","13","0.000630994226829448","0.115106967770578","11.61","561701, 386808, 368488, 492763, 553324, 30664, 321875, 406310, 100329779, 797132, 322309, 30767, 30100","IMPAIRED PROTEOSTASIS"
"APOPTOSIS","3","0.000635861842542917","0.485857746648546","5.36","566604, 492763, 58122","INCREASED APOPTOSIS ADENOMAS/CARCINOMAS FOLLICULAR CELL"
"GO:0003707","3","0.000651983322870002","0.249456051571081","9.38","555364, 30486, 30670","REDUCED MATURATION INDUCING STEROID RECEPTOR SIGNALLING OOCYTE"
"NUCLEAR RECEPTORS","3","0.000651983322870002","0.249456051571081","5.77","555364, 30486, 30670","ACTIVATION HEPATIC NUCLEAR RECEPTORS"
"ABNORMALITY OF THE LIVER","29","0.000673506228674626","0.0457985700616492","3.87","378972, 327601, 399483, 558088, 30265, 386709, 282672, 544667, 678540, 58076, 394190, 791518, 792391, 378453, 406713, 337598, 573689, 405861, 368229, 394028, 562149, 393963, 406691, 30767, 550537, 368206, 557518, 58071, 100000709","INCREASED INDUCTION OF UDPGT'S IN LIVER; INCREASED LIVER STEATOSIS; INCREASED LIVER STEATOSIS; N/A HEPATOTOXICITY HEPATOPATHY INCLUDING A CONSTELLATION OF OBSERVABLE EFFECTS; INDUCTION SUSTAINED HEPATOTOXICITY"
"OXIDATIVE DAMAGE","3","0.000676358154340205","0.480855608451206","15","566604, 492763, 399483","INCREASED OXIDATIVE DAMAGE"
"ESTROGEN RECEPTOR PATHWAY","2","0.00068238405608572","0.782404895124386","11.11","100150054, 30767","ACTIVATION ESTROGEN RECEPTOR"
"UPPER MOTOR NEURON DYSFUNCTION","25","0.000690363877208015","0.0606428388685658","5.27","368488, 436949, 558088, 30265, 100004133, 327075, 30442, 405839, 541548, 30705, 793321, 796865, 394190, 378453, 140540, 568332, 573689, 562350, 114426, 797715, 405861, 402974, 562149, 30225, 554127","DECREASE HISTAMINERGIC NEURON EXCITATION; OCCURRENCE CYTOPLASMIC VACUOLIZATION BILE DUCT CELL; OCCURRENCE CYTOPLASMIC VACUOLIZATION KUPFFER CELL"
"RENAL TUBULAR DYSFUNCTION","7","0.000692447677563347","0.261844428365122","26.92","558088, 266799, 792391, 140540, 573689, 368229, 30767","INCREASE HYPERPLASIA RENAL TUBULAR CELLS; INCREASE CYTOTOXICITY RENAL TUBULAR CELL; INCREASE ADENOMAS/CARCINOMAS RENAL TUBULAR; OCCURRENCE RENAL PROXIMAL TUBULAR NECROSIS"
"MALE REPRODUCTIVE SYSTEM NEOPLASM","2","0.000700820947175526","0.632687763085386","13.33","30483, 550537","MALFORMATION MALE REPRODUCTIVE TRACT; INDUCTION MALE REPRODUCTIVE TRACT; MALFORMED MALE REPRODUCTIVE TRACT"
"GO:0050665","2","0.000707480035053994","0.771313700624463","33.33","140540, 30767","DECREASED HYDROGEN PEROXIDE PRODUCTION"
"GO:0000003","34","0.000719733967055397","0.0439658335647377","16.75","335625, 58098, 368488, 566604, 399483, 406626, 30265, 321453, 399692, 494065, 30442, 405839, 541548, 30541, 796865, 30483, 58076, 100034503, 394048, 559921, 334098, 794176, 405860, 335236, 321442, 562350, 100003922, 562840, 797132, 322309, 30767, 550537, 369194, 30670","REDUCED REPRODUCTIVE SUCCESS; REPRODUCTIVE FAILURE"
"NADPH REGENERATION","1","0.000728",NA,"20","557518","INHIBITION HMG-COA REDUCTASE"
"ABNORMAL LIVER MORPHOLOGY","24","0.000737375385017567","0.0596894419164086","20.17","378972, 327601, 399483, 558088, 30265, 386709, 282672, 544667, 678540, 394190, 791518, 792391, 378453, 406713, 337598, 573689, 405861, 368229, 394028, 393963, 406691, 30767, 557518, 58071","INDUCTION LIVER “DYSFUNCTIONAL” CHANGES BY CGA 330050; INFLAMMATION LIVER; N/A LIVER FIBROSIS; INCREASE RBC CONGESTION IN LIVER; INCREASE LIVER AND SPLENIC HEMOSIDEROSIS; REDUCTION VITELLOGENIN SYNTHESIS IN LIVER; INCREASE VITELLOGENIN SYNTHESIS IN LIVER; FORMATION LIVER FIBROSIS; FORMATION LIVER TUMOR"
"GO:0007059","7","0.000757077772529619","0.27180302835152","15.91","767754, 30265, 335236, 337399, 322309, 321283, 114445","INCREASED CHROMOSOME MISSEGGREGATION"
"GO:0005515","6","0.000779136650302552","0.288850000915711","12.77","58098, 30265, 30482, 405860, 368206, 30670","BINDING SH-/SELEN-PROTEINS; COVALENT BINDING PROTEIN"
"GO:0046983","25","0.00080071991069246","0.0632151083734149","12.69","561701, 58098, 386966, 323696, 30705, 550403, 678540, 394048, 394190, 791518, 792391, 58122, 114426, 100003922, 321875, 336710, 30767, 317746, 436821, 368206, 140618, 369194, 557518, 554127, 436819","DIMERIZATION AHR/ARNT; REDUCED DIMERIZATION ARNT/HIF1-ALPHA"
"GO:0030728","1","0.000827",NA,"20","797132","DECREASE OVULATION"
"GO:0035357","1","0.000827",NA,"33.33","797132","ACTIVATION LXR ALPHA; DECREASED PPAR-ALPHA ACTIVATION; DECREASED PPAR-BETA ACTIVATION; DECREASED PPAR-GAMMA ACTIVATION; INHIBITION PPAR ALPHA; ACTIVATION OF SPECIFIC NUCLEAR RECEPTORS PPAR-GAMMA ACTIVATION; INCREASED PPAR-ALPHA ACTIVATION"
"OVULATION","1","0.000827",NA,"16.67","797132","DECREASE OVULATION; INTERRUPTION OVULATION"
"REGULATION OF PH","3","0.000842240052820978","0.988217780969159","21.43","436799, 286779, 30442","DECREASE INTRACELLULAR PH"
"G GLUTATHIONE METABOLISM","3","0.000845637785128414","0.743532766534992","37.5","553575, 406736, 114426","DEPLETION GSH"
"GO:0009653","3","0.000846151664262227","0.40573214395529","60","30541, 30126, 402974","INCREASED DEVELOPMENTAL DEFECTS"
"CONSTITUTIVE ANDROSTANE RECEPTOR PATHWAY","3","0.000847555644139336","0.678300478504279","10","368352, 324340, 567969","SUPPRESSION CONSTITUTIVE ANDROSTANE RECEPTOR NR1L3; ACTIVATION CONSTITUTIVE ANDROSTANE RECEPTOR"
"NRF2 PATHWAY","4","0.00086856220797348","0.535573970517202","10","553575, 791518, 406736, 369194","ACTIVATION NRF2"
"CHROMOSOME BREAKAGE","1","0.000876",NA,"25","30225","ALTERED MEIOTIC CHROMOSOME DYNAMICS; ALTERED CHROMOSOME NUMBER"
"DECREASED CIRCULATING LUTEINIZING HORMONE LEVEL","1","0.000876",NA,"12.5","30225","REDUCED LUTEINIZING HORMONE LH PLASMA; INCREASED LUTEINIZING HORMONE LH"
"GO:0001935","6","0.000898084876877228","0.154217481627765","16.67","116713, 30705, 544667, 791518, 797132, 30767","INCREASED PROLIFERATION ENDOTHELIAL CELLS"
"LOCOMOTORY BEHAVIOR","5","0.000905338476305479","0.293363303253519","8.06","561701, 386808, 30126, 142985, 402974","REDUCED SWIMMING SPEED; REDUCED SWIMMING PERFORMANCE"
"ABNORMAL FORM OF THE VERTEBRAL BODIES","4","0.000906071096621843","0.281461047968069","12.12","30705, 368229, 393963, 100000709","CLONAL EXPANSION/CELL PROLIFERATION TO FORM ALTERED HEPATIC FOCI AHF"
"SOMATIC MUTATION","6","0.000919540750089571","0.232225978196013","7.14","30265, 386966, 30705, 567969, 30225, 550537","INCREASED INDUCED MUTATIONS IN CRITICAL GENES; INCREASE MUTATIONS; INCREASE MUTATIONS IN CRITICAL GENES"
"RESPONSE TO ESTRADIOL","6","0.000960241039979887","0.185732159112952","20","116713, 566604, 30265, 30541, 794176, 30767","REDUCTION PLASMA 17BETA-ESTRADIOL CONCENTRATIONS"
"GO:0046903","29","0.00100011110531637","0.0670808196371883","12.55","335625, 561701, 58098, 406599, 569038, 100000085, 406549, 558088, 327075, 494065, 553324, 30442, 30705, 30126, 550403, 791518, 792391, 140540, 321442, 100003922, 323462, 445413, 436709, 393993, 100329779, 798575, 369194, 445164, 436819","SUPPRESSION VLDL SECRETION; INCREASE MUCIN PRODUCTION; INCREASED SECRETION OF LOCAL GROWTH FACTORS"
"INCREASED LEVEL OF HIPPURIC ACID IN URINE","2","0.00103608879928315","1.23124199613051","66.67","394190, 405861","INCREASED BLOOD URIC ACID CONCENTRATION"
"GO:0044703","21","0.00112651756953572","0.0762373769886461","18.1","335625, 58098, 368488, 406626, 30265, 321453, 494065, 30442, 796865, 394048, 334098, 794176, 405860, 335236, 321442, 100003922, 797132, 322309, 30767, 550537, 30670","N/A REPRODUCTIVE FAILURE"
"MORTALITY AGING","6","0.00125922281672557","0.20347201609271","23.08","406626, 394190, 406713, 797715, 30225, 436850","REDUCED FITNESS OR EVEN MORTALITY ACIDOSIS HYPOVOLEMIC SHOCK AND ORGAN DYSFUNCTION; INCREASE MORTALITY; INCREASED MORTALITY"
"PANCREATIC HYPOPLASIA","4","0.00129251153776986","0.393505050431726","57.14","58076, 792391, 393963, 30767","INCREASED PANCREATIC ACINAR TUMORS"
"LIPID ACCUMULATION IN HEPATOCYTES","8","0.00130986741813446","0.221151583748729","25","378972, 558088, 282672, 394190, 792391, 378453, 406713, 368229","INCREASE PRENEOPLASTIC FOCI HEPATOCYTES"
"RESPONSE TO REACTIVE OXYGEN SPECIES","7","0.00137482523666233","0.256389085943759","12.5","566604, 100150054, 368352, 567969, 791518, 797132, 394172","INCREASED REACTIVE OXYGEN SPECIES"
"ABNORMAL RENAL TUBULE MORPHOLOGY","3","0.00153732702396664","0.175844273742257","33.33","327601, 562350, 368229","OCCURRENCE CYSTIC DILATATION RENAL TUBULE; OCCURRENCE CYTOPLASMIC VACUOLIZATION RENAL TUBULE"
"GO:0019882","7","0.00163393116343471","0.331180695920989","11.86","368488, 100000085, 767754, 321453, 445413, 30388, 436709","GENERATION OF NOVEL EPITOPES  ANTIGEN PRESENTATION"
"NEURON CELLULAR HOMEOSTASIS","2","0.00171153147794599","0.877400278243624","33.33","30725, 100003922","ALTERED NEUROPHYSIOLOGY"
"GO:0030520","1","0.00177",NA,"12.5","30541","ACTIVATION ESTROGEN RECEPTOR ALPHA"
"STEROID HORMONE MEDIATED SIGNALING PATHWAY","3","0.00182901957097644","0.117350534146732","2.94","30541, 30486, 797132","DECREASE STEROIDOGENIC ACUTE REGULATORY PROTEIN STAR; DECREASED HSD17B10 EXPRESSION; REDUCED MATURATION INDUCING STEROID PLASMA"
"GO:0030545","3","0.00186571717584804","0.837511781090662","5.08","335625, 321442, 369194","DESENSITIZATION NICOTINIC ACETYLCHOLINE RECEPTOR"
"GO:0006809","1","0.00187",NA,"33.33","58071","DEPLETION NITRIC OXIDE"
"GO:0008015","1","0.00187",NA,"33.33","58071","INSUFFICIENCY VASCULAR"
"GO:0007568","17","0.00208583330848809","0.0898867966069437","19.77","58098, 492763, 100000085, 399483, 393162, 559504, 321453, 30442, 30664, 394048, 794176, 436608, 100003922, 402974, 797132, 798575, 30767","ACCELERATED AGING"
"GO:0030163","19","0.0020867791456884","0.102675127194293","12.42","58098, 368488, 30265, 321453, 567969, 30664, 393722, 114426, 445413, 30388, 436709, 321875, 406310, 100329779, 797132, 322309, 436713, 114445, 30100","INCREASED CATABOLISM OF MUSCLE PROTEIN"
"ABNORMAL CIRCULATING FATTY ACID CONCENTRATION","2","0.00216251936407515","1.00527681325379","22.22","266799, 394190","ACCUMULATION FATTY ACID"
"DECREASED PLASMA CARNITINE","2","0.00216251936407515","1.00527681325379","28.57","266799, 394190","REDUCTION PLASMA VITELLOGENIN CONCENTRATIONS; INCREASE PLASMA VITELLOGENIN CONCENTRATIONS; DECREASED RENAL PLASMA FLOW; INCREASED PLASMA TYROSINE; DECREASED PROSTAGLANDIN F2ALPHA CONCENTRATION PLASMA"
"CELL MIGRATION AND INVASION THROUGH P75NTR","2","0.00218997716883076","0.424318443610606","11.11","378972, 30767","INCREASED INVASION"
"G JAK STAT SIGNALING PATHWAY","2","0.00218997716883076","0.424318443610606","12.5","378972, 30767","ACTIVATION JAK/STAT PATHWAY"
"GO:0007009","3","0.00238412262424222","0.825661202077214","33.33","378972, 327075, 369194","NARCOSIS"
"TRIGLYCERIDE METABOLIC PROCESS","4","0.00242118606036715","0.521971720493743","25","558088, 368352, 406713, 797132","ACCUMULATION TRIGLYCERIDE"
"G TGF BETA SIGNALING PATHWAY","3","0.00249118989596393","0.789254059969389","4.41","406685, 100329779, 369194","ACTIVATION TGF-BETA PATHWAY; UP REGULATION TGFBETA1 EXPRESSION"
"FAT MALABSORPTION","2","0.00269250812440743","0.824019250283912","50","406713, 393963","INDUCTION MICROVESICULAR FAT"
"REGULATION OF ATPASE ACTIVITY","4","0.0028578650184952","0.454402728739184","25","386709, 553324, 797132, 58071","INHIBITION CA++ ATPASE"
"GO:0008283","2","0.00295296461204668","0.332522792156777","22.22","30767, 321283","PROLIFERATION CELL PROLIFERATION IN THE ABSENCE OF CYTOTOXICITY; ACTIVATION/PROLIFERATION T-CELLS; ALTERATIONS CELLULAR PROLIFERATION / HYPERPLASIA; INCREASE PROLIFERATION LEYDIG CELL; INCREASE MITOGENIC CELL PROLIFERATION HEPATOCYTES; INCREASE HYPERTROPHY AND PROLIFERATION FOLLICULAR CELL; INCREASE REGENERATIVE CELL PROLIFERATION CORNEAL CELLS; INCREASE REGENERATIVE CELL PROLIFERATION FORESTOMACH EPITHELIAL CELLS; INCREASE REGENERATIVE CELL PROLIFERATION HEPATOCYTES; INCREASE REGENERATIVE CELL PROLIFERATION UROTHELIAL CELLS; INCREASE CELL PROLIFERATION; INCREASE PROLIFERATION OF GOBLET CELLS; INCREASED HYPERTROPHY AND PROLIFERATION FOLLICULAR CELL; PROLIFERATION/CLONAL EXPANSION SMOOTH MUSCLE; INCREASED CELLULAR PROLIFERATION / HYPERPLASIA OF ACINAR CELLS; PROLIFERATION/CLONAL EXPANSION ABERRANT BASAL CELLS; INCREASED CELL PROLIFERATION MESOTHELIUM; INCREASE CELL PROLIFERATION EPITHELIAL CELLS"
"REGULATION OF WNT SIGNALING PATHWAY","8","0.00317911654409908","0.232471677896485","10.13","30265, 30664, 794176, 406685, 445413, 30388, 436709, 550537","INHIBITION WNT PATHWAY"
"GO:0046562","1","0.00327",NA,"3.7","282672","DECREASED GLUCOSE OXIDASE ENZYME ACTIVITY"
"GLYCOLYSIS AND GLUCONEOGENESIS","1","0.00327",NA,"4.35","282672","DECREASED PCK1 EXPRESSION CONTROL POINT FOR GLYCOLYSIS/GLUCONEOGENESIS PATHWAY"
"PYRUVATE METABOLIC PROCESS","5","0.00341472805351098","0.152556018177896","8.93","282672, 335236, 562350, 797715, 568298","INHIBITION 4-HYDROXYPHENYL-PYRUVATE DIOXYGENASE HPPD ENZYME"
"GO:0003824","9","0.00347077487592569","0.202119682273117","13.85","436949, 494065, 550403, 394190, 114426, 436850, 317746, 557518, 393793","DECREASED DHB4/HSD17B4; DECREASE INCORPORATION OF ACTIVE IODIDE INTO IODOTYROSINES; INHIBITION PROLYL HYDROXYLASES; INHIBITION UROD; DECREASE AKT/ENOS ACTIVITY; INHIBITION DEIODINASE 2; INHIBITION DEIODINASE 1; INHIBITION IODOTYROSINE DEIODINASE IYD; INHIBITION DEIODINASE 3; INHIBITION DUAL OXIDASE; INDUCTION UPREGULATION OF GLUCURONYLTRANSFERASE ACTIVITY"
"GO:0006915","4","0.00363023678070118","0.568739908255244","12.9","566604, 492763, 259303, 445283","CHANGES/INHIBITION CELLULAR HOMEOSTASIS AND APOPTOSIS; DECREASED APOPTOSIS EPITHELIAL CELLS; INCREASED APOPTOSIS DECREASED LEYDIG CELLS"
"GO:0042698","3","0.00381142629551173","0.757201736910383","13.64","566604, 797132, 369194","IRREGULARITIES OVARIAN CYCLE"
"GO:0048856","1","0.00418",NA,"8.33","30486","ALTERED NEUROANATOMY"
"CTOME FOXO MEDIATED TRANSCRIPTION","4","0.00465069783831196","0.28872190660247","14.29","378972, 567969, 797132, 550537","ACTIVATION FOXO"
"GO:0045444","6","0.00504898916025942","0.277372075873467","14.63","378972, 58098, 567253, 567969, 797132, 322309","INCREASED ADIPOGENESIS"
"GO:0048813","1","0.0055",NA,"7.69","550537","ABERRANT DENDRITIC MORPHOLOGY"
"DNA DAMAGE RESPONSE","5","0.00719881854237084","0.325346226851613","8.62","566604, 492763, 393162, 100004133, 394048","INCREASED DNA DAMAGE-REPAIR"
"FAS LIGAND FASL PATHWAY AND STRESS INDUCTION OF HEAT SHOCK PROTEINS HSP REGULATION","3","0.00848713384503935","0.667246777543057","11.54","566604, 492763, 327321","ACTIVATION FAS; UP REGULATION FAS"
"HUMAN THYROID STIMULATING HORMONE TSH SIGNALING PATHWAY","1","0.00872",NA,"0.93","30767","DECREASED TRIIODOTHYRONINE T3 IN SERUM; INCREASE THYROID-STIMULATING HORMONE TSH; DECREASED THYROXINE T4 IN SERUM; INCREASED THYROID-STIMULATING HORMONE TSH"
"SIGNALING OF HEPATOCYTE GROWTH FACTOR RECEPTOR","1","0.00872",NA,"2.94","30767","OCCURRENCE CYTOPLASMIC VACUOLIZATION HEPATOCYTE; OCCURRENCE BALLOONING DEGENERATION HEPATOCYTE"
"GO:0006839","9","0.00933621288250214","0.22125871906375","19.57","336957, 406301, 767750, 406599, 415253, 558088, 30664, 30767, 323361","REDUCTION CHOLESTEROL TRANSPORT IN MITOCHONDRIA"
"CTOME CELLULAR RESPONSE TO HYPOXIA","4","0.0158691995280774","0.604858775397752","9.3","445413, 30388, 436709, 436713","N/A HYPOXIA"
"G VEGF SIGNALING PATHWAY","3","0.0186420139411899","0.48165689279135","14.29","378972, 492763, 327321","REDUCED PRODUCTION VEGF"
"GO:0022414","3","0.0210143514899716","0.866157056656836","8.33","399692, 394048, 564017","INCREASED REPRODUCTIVE SUCCESS"
"GO:0006635","2","0.0394525030891577","1.31218644933731","10","378972, 558088","DECREASED PEROXISOMAL FATTY ACID BETA OXIDATION OF FATTY ACIDS; DECREASED MITOCHONDRIAL FATTY ACID BETA OXIDATION; DECREASED MITOCHONDRIAL FATTY ACID BETA-OXIDATION; INHIBITION MITOCHONDRIAL FATTY ACID BETA-OXIDATION"
"SYNTHESIS AND DEGRADATION OF KETONE BODIES","1","0.0571",NA,"16.67","394190","NOT INCREASED CIRCULATING KETONE BODIES"
"CTOME SYNTHESIS OF KETONE BODIES","1","0.0571",NA,"12.5","394190","DECREASED KETOGENESIS PRODUCTION OF KETONE BODIES; DECREASED KETOGENESIS"
"GO:1903009","3","0.107960076121251","0.716479202125609","8.82","445413, 30388, 436709","DECREASE GTPCH-1"
"GO:0015908","3","0.171133486732378","0.719719787064842","13.64","378972, 406599, 558088","INCREASED FA INFLUX"
"RESPONSE TO NITRIC OXIDE","1","0.187",NA,"14.29","567969","DECREASED NITRIC OXIDE"
"GO:0005125","1","1.29",NA,"4","369194","ACTIVATION INFLAMMATORY CYTOKINES CHEMOKINES CYTOPROTECTIVE GENE PATHWAYS"
